Semi-Annual Consolidated Statement Of Cash Flows

ROHTO PHARMACEUTICAL CO.,LTD. - Filing #7249269

Concept As at
2025-03-31
2024-04-01 to
2025-03-31
2023-04-01 to
2024-03-31
As at
2024-03-31
As at
2023-03-31
Semi-annual consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Subtotal
47,018,000,000 JPY
42,653,000,000 JPY
Interest and dividends received
2,005,000,000 JPY
1,762,000,000 JPY
Interest paid
-888,000,000 JPY
-200,000,000 JPY
Income taxes paid
-11,237,000,000 JPY
-10,041,000,000 JPY
Net cash provided by (used in) operating activities
36,917,000,000 JPY
34,245,000,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-9,080,000,000 JPY
-7,979,000,000 JPY
Proceeds from sale of property, plant and equipment
26,000,000 JPY
272,000,000 JPY
Purchase of investment securities
-6,832,000,000 JPY
-7,531,000,000 JPY
Purchase of shares of subsidiaries resulting in change in scope of consolidation
-74,479,000,000 JPY
JPY
Other, net
-18,000,000 JPY
0 JPY
Net cash provided by (used in) investing activities
-89,170,000,000 JPY
-16,317,000,000 JPY
Cash flows from financing activities
Proceeds from long-term borrowings
14,908,000,000 JPY
1,605,000,000 JPY
Repayments of long-term borrowings
-5,961,000,000 JPY
-3,484,000,000 JPY
Purchase of treasury shares
-5,000,000,000 JPY
0 JPY
Dividends paid
-7,072,000,000 JPY
-5,475,000,000 JPY
Net cash provided by (used in) financing activities
35,319,000,000 JPY
-13,784,000,000 JPY
Dividends paid to non-controlling interests
-1,000,000 JPY
-1,000,000 JPY
Purchase of shares of subsidiaries not resulting in change in scope of consolidation
-13,505,000,000 JPY
-6,144,000,000 JPY
Other, net
-2,626,000,000 JPY
-938,000,000 JPY
Effect of exchange rate change on cash and cash equivalents
3,374,000,000 JPY
4,703,000,000 JPY
Net increase (decrease) in cash and cash equivalents
-13,558,000,000 JPY
8,847,000,000 JPY
Cash and cash equivalents
73,221,000,000 JPY
86,562,000,000 JPY
77,691,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.